StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3083% above fair value
$13.09−0.36 (-2.68%)

Close on Nov 20, 2026Market cap $459.03MP/E –Yield –

Fennec Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Fennec Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2023 was $19.99M. For fiscal 2023 it was $19.99M, up 1279.8% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2023Dec 31, 2023$19.99M+1279.8%
FY2022Dec 31, 2022$1.45M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$9.05M–
Q3 FY2023Sep 30, 2023$6.18M–
Q2 FY2023Jun 30, 2023$3.18M–
Q1 FY2023Mar 31, 2023$1.58M–

More Fennec Pharmaceuticals figures

See a number that looks wrong?